Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience
Related Experiment Video
Updated: May 6, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Joyce Wong1, Abigail L Koch, Jeremiah L Deneve
1Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA, joyce.wong02@gmail.com.
Introduction:
Cytoreduction with heated intraperitoneal chemotherapy (HIPEC) has demonstrated improved overall survival (OS) in malignant peritoneal mesothelioma (MPM). The role of repeated HIPEC for MPM is less clear.
Methods:
An institutional review board-approved database of MPM patients was analyzed for clinical factors and outcomes.
Results:
From June 2004 to March 2012, 29 patients underwent surgical treatment for mesothelioma. HIPEC was aborted in 3 and completed in 26; 8 underwent additional repeat HIPEC. The majority was male (62 %), median age 66 years. There was no significant difference in surgery duration, blood loss, or hospital-stay-duration between initial and repeat HIPEC. Cisplatin was the chemotherapy used. Complications occurred in 17 (65 %) initial and 6 (50 %) repeat HIPEC, with wound complications being most common. Reoperation was less common (4 % initial and 25 % repeat), and perioperative death was rare (4 % initial, 0 % repeat). Fourteen (54 %) initial and seven (58 %) repeat HIPEC patients received adjuvant chemotherapy. Median time from HIPEC to initiation of chemotherapy was not different between initial and repeat HIPEC (8.8 and 4.6 months, respectively, p = 0.68). Median treatment-free time (time from initial to repeat HIPEC or chemotherapy) also was not different between initial and repeat HIPEC (8.8 and 6.3 months, respectively, p = 0.92). Median OS for the cohort was 41.2 months. Patients who underwent repeat HIPEC had improved median OS (80 months) versus single HIPEC (27.2 months; p = 0.007). A lower peritoneal carcinoma index and complete cytoreduction were associated positively with OS.
Conclusions:
Cytoreduction and HIPEC for MPM are associated with longer OS. Patients who are candidates for repeat HIPEC may derive an even greater OS advantage.
Insights
Repeat heated intraperitoneal chemotherapy (HIPEC) for malignant peritoneal mesothelioma (MPM) may significantly improve overall survival (OS). Patients undergoing repeat HIPEC showed a median OS of 80 months compared to 27.2 months for single HIPEC.
Area of Science:
- Oncology
- Surgical Oncology
- Chemotherapy
Background:
- Cytoreduction with heated intraperitoneal chemotherapy (HIPEC) improves survival in malignant peritoneal mesothelioma (MPM).
- The efficacy of repeat HIPEC in MPM patients remains less understood.
Purpose of the Study:
- To evaluate the outcomes and survival benefits of repeat HIPEC in MPM patients.
- To compare the safety and efficacy of initial versus repeat HIPEC procedures.
Main Methods:
- Retrospective analysis of an institutional review board-approved database of MPM patients.
- Evaluation of clinical factors, HIPEC procedure details, complications, and overall survival (OS).
Main Results:
- Eight of 26 patients completed HIPEC underwent repeat HIPEC; no significant differences in surgery duration, blood loss, or hospital stay.
- Complication rates were 65% for initial and 50% for repeat HIPEC, with wound complications most common.
- Patients receiving repeat HIPEC demonstrated a significantly improved median OS (80 months) compared to single HIPEC (27.2 months).
Conclusions:
- Cytoreduction and HIPEC are associated with prolonged OS in MPM.
- Repeat HIPEC may offer a substantial survival advantage for eligible MPM patients.
More Related Videos
09:31Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
04:22Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023